UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 4, 2015
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware | 000-30402 | 91-1949078 |
(State or other jurisdiction | (Commission File Number) | (IRS Employer |
of Incorporation) |
| Identification Number) |
|
#24-05 Shaw Centre Singapore 228208 |
|
| (Address of principal executive offices) |
|
| Telephone: +1 (646) 650-1351 Facsimile: +32 8172 5651 |
|
(Registrant’s Telephone and Facsimile Number) | ||
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
VOLITIONRX LIMITED
Form 8-K
Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing:
As previously announced, on November 4, 2015, VolitionRx Limited hosted a conference call discussing its financial results for the quarter ended September 30, 2015. The conference call was announced by a widely disseminated press release and was made available to the public via audio webcast. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the transcript of the conference call.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Number | Description |
99.1 | Transcript of Conference Call held on November 4, 2015. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VOLITIONRX LIMITED
| |
Date: November 10, 2015 | By: | /s/ Cameron Reynolds |
|
| Cameron Reynolds |
|
| Chief Executive Officer & President |
EXHIBIT INDEX
Exhibit Number | Description |
99.1 | Transcript of Conference Call held on November 4, 2015. |